R&D News | pharmaphorum

News

Surfing on new Duchenne data, Wave charges $175m offering

Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to its highest level in a year and could lead to discussions with re

News

AI firm Generate signs $1bn discovery deal with Novartis

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.

News

football going into the net past goalkeeper to score

UCB, Biogen lupus drug scores in phase 3 trial

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of

News

Sanofi's tolebrutinib cuts MS progression by 31% in trial

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data

News

Job losses loom at Achilles as TIL therapy platform is cut

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping its R&D in tumour-infiltrating lymphocyte (TIL) therapies for

News

Respiratory biotech Upstream joins Nasdaq IPO surge

Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.

Surfing on new Duchenne data, Wave charges $175m offering

AI firm Generate signs $1bn discovery deal with Novartis

UCB, Biogen lupus drug scores in phase 3 trial

Sanofi's tolebrutinib cuts MS progression by 31% in trial

Job losses loom at Achilles as TIL therapy platform is cut

Respiratory biotech Upstream joins Nasdaq IPO surge

UK's Claret Capital raises €575m for European biotechs

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks